This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Protalix Submits BLA for Fabry Disease Candidate PRX-102
by Zacks Equity Research
Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.
Protalix Finalizes Accelerated Approval Pathway for PRX-102
by Zacks Equity Research
Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.
Protalix (PLX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protalix (PLX) delivered earnings and revenue surprises of 50.00% and 22.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protalix Completes Enrollment in Third Fabry Disease Study
by Zacks Equity Research
Protalix (PLX) completes enrollment in another phase III study of pegunigalsidase alfa (PRX 102) to treat Fabry disease.
Protalix (PLX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protalix (PLX) delivered earnings and revenue surprises of -66.67% and 4.23%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protalix (PLX) Completes Enrollment in Fabry Disease Study
by Zacks Equity Research
Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.
Protalix (PLX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protalix (PLX) delivered earnings and revenue surprises of -66.67% and 2.85%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Protalix (PLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.
Do Options Traders Know Something About Protalix (PLX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Protalix (PLX) stock based on the movements in the options market lately.
Implied Volatility Surging for Protalix (PLX) Stock Options
by Zacks Equity Research
Protalix (PLX) needs investors to pay close attention to the stock based on moves in the options market lately.
Moving Average Crossover Alert: Protalix BioTherapeutics
by Zacks Equity Research
Protalix BioTherapeutics, Inc. (PLX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Protalix (PLX) delivered earnings and revenue surprises of -150.00% and -91.71%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Protalix (PLX) delivered earnings and revenue surprises of -33.33% and -71.34%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Protalix (PLX) Fabry Disease Candidate Gets Orphan Status
by Zacks Equity Research
Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.
Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9%
by Zacks Equity Research
Protalix BioTherapeutics(PLX) saw its shares rise 9% on the day.
Are Options Traders Betting on a Big Move in Protalix BioTherapeutics (PLX) Stock?
by Zacks Equity Research
Investors in Protalix BioTherapeutics, Inc. (PLX) need to pay close attention to the stock based on moves in the options market lately.
Do Options Traders Know Something About Protalix (PLX) Stock We Don't?
by Zacks Equity Research
Options traders are pricing in a big move for Protalix BioTherapeutics (PLX) shares as it has huge implied volatility
Protalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%
by Zacks Equity Research
Protalix BioTherapeutics, Inc. (PLX)was a big mover last session, as the company saw its shares rise nearly 12% on the day.